350 related articles for article (PubMed ID: 31597845)
21. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.
Fajgenbaum DC; van Rhee F; Nabel CS
Blood; 2014 May; 123(19):2924-33. PubMed ID: 24622327
[TBL] [Abstract][Full Text] [Related]
22. Multicentric Castlemans disease. Symptoms, diagnostics and therapy.
Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Sandecká V; Krejčí M; Štork M; Ševčíková S; Král Z
Vnitr Lek; 2022; 68(1):41-53. PubMed ID: 35459346
[TBL] [Abstract][Full Text] [Related]
23. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.
Fajgenbaum DC; Uldrick TS; Bagg A; Frank D; Wu D; Srkalovic G; Simpson D; Liu AY; Menke D; Chandrakasan S; Lechowicz MJ; Wong RS; Pierson S; Paessler M; Rossi JF; Ide M; Ruth J; Croglio M; Suarez A; Krymskaya V; Chadburn A; Colleoni G; Nasta S; Jayanthan R; Nabel CS; Casper C; Dispenzieri A; Fosså A; Kelleher D; Kurzrock R; Voorhees P; Dogan A; Yoshizaki K; van Rhee F; Oksenhendler E; Jaffe ES; Elenitoba-Johnson KS; Lim MS
Blood; 2017 Mar; 129(12):1646-1657. PubMed ID: 28087540
[TBL] [Abstract][Full Text] [Related]
24. Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.
Nagy A; Bhaduri A; Shahmarvand N; Shahryari J; Zehnder JL; Warnke RA; Mughal T; Ali S; Ohgami RS
Blood Adv; 2018 Mar; 2(5):481-491. PubMed ID: 29496669
[TBL] [Abstract][Full Text] [Related]
25. TAFRO Syndrome.
Igawa T; Sato Y
Hematol Oncol Clin North Am; 2018 Feb; 32(1):107-118. PubMed ID: 29157612
[TBL] [Abstract][Full Text] [Related]
26. Idiopathic multicentric Castleman disease with positive antiphospholipid antibody: atypical and undiagnosed autoimmune disease?
Nishimura Y; Nishikori A; Sawada H; Czech T; Otsuka Y; Nishimura MF; Mizuno H; Sawa N; Momose S; Ohsawa K; Otsuka F; Sato Y
J Clin Exp Hematop; 2022 Jun; 62(2):99-105. PubMed ID: 35249898
[TBL] [Abstract][Full Text] [Related]
27. T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms.
Fraticelli S; Lucioni M; Neri G; Marchiori D; Cristinelli C; Merli M; Monaco R; Borra T; Lazzaro A; Uccella S; Arcaini L; Paulli M
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175521
[TBL] [Abstract][Full Text] [Related]
28. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.
Gao YH; Liu YT; Zhang MY; Li SY; Fajgenbaum DC; Zhang L; Li J
Br J Haematol; 2024 May; 204(5):1830-1837. PubMed ID: 38356434
[TBL] [Abstract][Full Text] [Related]
29. Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease.
Pierson SK; Stonestrom AJ; Shilling D; Ruth J; Nabel CS; Singh A; Ren Y; Stone K; Li H; van Rhee F; Fajgenbaum DC
Am J Hematol; 2018 Jul; 93(7):902-912. PubMed ID: 29675946
[TBL] [Abstract][Full Text] [Related]
30. Recent Advances in Castleman Disease.
Hoffmann C; Hentrich M; Tiemann M; Rosenwald A; Weber F; Willenbacher W; Hübel K
Oncol Res Treat; 2022; 45(11):693-704. PubMed ID: 36219975
[TBL] [Abstract][Full Text] [Related]
31. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
Koga T; Sumiyoshi R; Kawakami A; Yoshizaki K
Mod Rheumatol; 2019 Mar; 29(2):302-305. PubMed ID: 30285516
[TBL] [Abstract][Full Text] [Related]
32. TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy.
Williams C; Phillips A; Aggarwal V; Slonim LB; Fajgenbaum DC; Karmali R
Case Rep Oncol; 2021; 14(3):1359-1365. PubMed ID: 34720942
[TBL] [Abstract][Full Text] [Related]
33. From Castleman disease histopathological features to idiopathic multicentric Castleman disease: a multiparametric approach to exclude potential iMCD histopathological mimickers.
Rodriguez Merino L; Pomares AA; Arce JR; Montes-Moreno S
J Clin Pathol; 2024 Apr; 77(5):318-323. PubMed ID: 36690434
[TBL] [Abstract][Full Text] [Related]
34. Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease.
Nishikori A; Nishimura MF; Nishimura Y; Otsuka F; Maehama K; Ohsawa K; Momose S; Nakamura N; Sato Y
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142213
[TBL] [Abstract][Full Text] [Related]
35. Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia--a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity?
Masaki Y; Nakajima A; Iwao H; Kurose N; Sato T; Nakamura T; Miki M; Sakai T; Kawanami T; Sawaki T; Fujita Y; Tanaka M; Fukushima T; Okazaki T; Umehara H
J Clin Exp Hematop; 2013; 53(1):79-85. PubMed ID: 23801138
[TBL] [Abstract][Full Text] [Related]
36. The potential role of follicular helper T cells in idiopathic multicentric Castleman disease with and without TAFRO syndrome.
Kurose N; Guo X; Shioya A; Mizutani KI; Kumagai M; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Nakamura S; Yamada S
Pathol Res Pract; 2019 Oct; 215(10):152563. PubMed ID: 31358479
[TBL] [Abstract][Full Text] [Related]
37. Epidemiology of Castleman Disease.
Simpson D
Hematol Oncol Clin North Am; 2018 Feb; 32(1):1-10. PubMed ID: 29157611
[TBL] [Abstract][Full Text] [Related]
38. Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease.
Rubenstein AI; Pierson SK; Shyamsundar S; Bustamante MS; Gonzalez MV; Milller ID; Brandstadter JD; Mumau MD; Fajgenbaum DC
Br J Haematol; 2024 Mar; 204(3):921-930. PubMed ID: 38168727
[TBL] [Abstract][Full Text] [Related]
39. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.
Lust H; Gong S; Remiker A; Rossoff J
Pediatr Blood Cancer; 2021 Oct; 68(10):e29261. PubMed ID: 34302703
[TBL] [Abstract][Full Text] [Related]
40. Castleman disease.
Carbone A; Borok M; Damania B; Gloghini A; Polizzotto MN; Jayanthan RK; Fajgenbaum DC; Bower M
Nat Rev Dis Primers; 2021 Nov; 7(1):84. PubMed ID: 34824298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
